In case of multicentre trials, the sponsor will appoint one the participating investigators to become coordinating investigator (CI) in accordance with § 4 sec. 25 Medicinal Products Act or § 3 sec. 30 Medical Devices Act. The ethics committee responsible for the coordinating investigator automatically becomes the central ethics committee, to which the application for…
